Rapport Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGN ATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Rapport Therapeutics, Inc. | ||
| Date: March 10, 2026 | By: | /s/ Abraham N. Ceesay |
|---|---|---|
| Abraham N. Ceesay, M.B.A. | ||
| Chief Executive Officer and Director | ||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Abraham N. Ceesay, M.B.A. and Troy Ignelzi, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Annual Report on Form 10-K has been signed by the following person in the capacities and on the date indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Abraham N. Ceesay | Chief Executive Officer and Director | March 10, 2026 |
| Abraham N. Ceesay, M.B.A. | (Principal Executive Officer) | |
| /s/ Troy Ignelzi | Chief Financial Officer | March 10, 2026 |
| Troy Ignelzi | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Steven M. Paul | Director and Chairman | March 10, 2026 |
| Steven M. Paul, M.D. | ||
| /s/ James I. Healy | Director | March 10, 2026 |
| James I. Healy, M.D., Ph.D. | ||
| /s/ John Maraganore | Director | March 10, 2026 |
| John Maraganore, Ph.D. | ||
| /s/ Paul Silva | Director | March 10, 2026 |
| Paul Silva | ||
| /s/ Raymond Sanchez | Director | March 10, 2026 |
| Raymond Sanchez, M.D. | ||
| /s/ Robert J. Perez | Director | March 10, 2026 |
| Robert J. Perez | ||
| /s/ Reid Huber | Director | March 10, 2026 |
| Reid Huber, Ph.D. | ||
| /s/ Wendy B. Young | Director | March 10, 2026 |
| Wendy B. Young, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.